Venetoclax to Augment Epigenetic Modification and Chemotherapy

This study tests venetoclax — a drug that blocks proteins that help cancer cells survive — combined with epigenetic (gene-regulating) drugs and chemotherapy for children and young adults with relapsed or difficult-to-treat acute myeloid leukemia (AML), a serious blood cancer. **You may be eligible if...** - You have AML that has relapsed (come back) at least once, OR failed to go into remission after multiple attempts at induction chemotherapy - Patients with treatment-related AML (tAML), including newly diagnosed tAML, may also be eligible - You have measurable leukemia in the bone marrow - You may have cancer in the brain or other sites outside the bone marrow **You may NOT be eligible if...** - You have had prior cranial (brain) radiation during this treatment protocol - You have severe organ dysfunction that makes chemotherapy unsafe - You have had certain prior treatments that conflict with the study protocol Talk to your doctor to see if this trial is right for you.